Navigation Links
FDA Grants Standard Review for GSK's Experimental HPV Vaccine Cervarix

GlaxoSmithKline on Thursday announced that FDA has granted a standard 10-month review of its experimental human papillomavirus vaccine Cervarix, Reuters reports. A GSK spokesperson on Thursday said FDA declined to grant priority review, which could have been completed in six months.

Cervarix and Merck's HPV vaccine Gardasil have been shown to be 100% effective in preventing infection with HPV strains 16 and 18, which together cause about 70% of cervical cancer cases. Researchers in a 2006 study published in the online edition of the Lancet also found that Cervarix prevented infection with HPV strains 31 and 45, which together with strains 16 and 18 cause more than 80% of cervical cancer cases. GSK in January announced that it would begin a trial to determine whether Cervarix provides better protection against cervical cancer than Gardasil.

The Australian Therapeutic Goods Administration last week granted the first major market license for Cervarix, approving the vaccine for girls and women ages 10 to 45. According to Reuters, the European Medicines Agency could recommend the vaccine next month. FDA will most likely take action on GSK's application in January 2008, according to analysts at Evolution Securities.


'"/>




Page: 1

Related medicine news :

1. AIDS Funding Grants Dependant on Tracking Patients Names Efficiently
2. Rice University wins Prestigious Grants from HHMI
3. Norway Grants $80 mn to Indias Health Mission
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. NIMH Grants Funds To Study The Impact Of Terrorism
6. US Grants Rs.190 mn to Fight TB in India
7. Gates Foundation Grants $23mn for AIDS programme in India
8. FDA Grants Approval to First Bird Flu Vaccine
9. Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses
10. Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses
11. Angioplasty Should be the Standard
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, ... the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where ... city’s history as home to some of the world’s leading providers of cereal and ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
Breaking Medicine Technology: